The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Sponsor
Chulalongkorn University
Study ID
NCT06030843
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Empagliflozin in Cardiorenal Syndrome Type 1

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Empagliflozin 10 MG — DRUG
    Empagliflozin 10 MG
  • Placebo — DRUG
    Matching placebo containing Lactose content (0.26 gram)

Study Details

Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.

Key Dates

Start date
Mar 1, 2025
Status verified
Aug 2025
Primary completion
Nov 30, 2025
Completion
Dec 31, 2026

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
    Empagliflozin 10 mg po OD
  • Placebo Comparator: Placebo
    Matching placebo

Primary Outcome Measure

MAKE30 [ Time Frame: 30 days ]

Central Contacts